West Pharmaceutical (WST) Misses Q2 EPS by 5c; Adjusts FY11 Outlook
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $353.71 --0%
Revenue Growth %: +9.6%
Financial Fact:
Gross profit: 121.1M
Today's EPS Names:
CCEL, MHGU, PLG, More
Revenue Growth %: +9.6%
Financial Fact:
Gross profit: 121.1M
Today's EPS Names:
CCEL, MHGU, PLG, More
Join SI Premium – FREE
West Pharmaceutical Services, Inc. (NYSE: WST) reported Q2 EPS of $0.62, $0.05 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $307.9 million versus the consensus estimate of $299.45 million.
West Pharmaceutical Services, Inc. sees FY2011 EPS of $2.30-$2.40, versus prior guidance of $2.30-$2.50 and the consensus of $2.38. West Pharmaceutical Services, Inc. sees FY2011 revenue of $1.17-$1.20 billion, versus prior guidance of $1.16-$1.19 billion and the consensus of $1.18 billion.
West Pharmaceutical Services, Inc. sees FY2011 EPS of $2.30-$2.40, versus prior guidance of $2.30-$2.50 and the consensus of $2.38. West Pharmaceutical Services, Inc. sees FY2011 revenue of $1.17-$1.20 billion, versus prior guidance of $1.16-$1.19 billion and the consensus of $1.18 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- MarketWise Q2 billings rise 56% year-over-year to $91M
- Ionis Pharmaceuticals (IONS) reaffirms guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
